Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fujifilm Recalls ED-530XT Duodenoscope In 'Abundance Of Caution'

Executive Summary

Fujifilm Medical Systems issued an urgent medical device correction and removal for its ED-530XT duodenoscope on July 21. The company said it needed to update and replace the scope's forceps elevator mechanism and O-ring seal, distal end cap, and operations manuals in an "abundance of caution" to reduce risk to public health from inadequate reprocessing. FDA said it was working with Fujifilm on the correction.

You may also be interested in...



Fujifilm Asks Customers To Turn In Older Duodenoscopes

Fujifilm is removing its legacy 250/450 duodenoscope models from clinical use and replacing them with the ED-530XT model, telling customers that they will receive new scopes and cleaning accessories at no cost. Some older models were involved in antimicrobial drug-resistant contamination outbreaks.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.

HHS Secretary Nominee Becerra Commits To Telehealth Expansion, Procedure Price Transparency

At two recent confirmation hearings, HHS secretary nominee Xavier Becerra promised Senators he would help expand telehealth and procedure price transparency.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT105212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel